课题基金 / 基金详情

PHASE II DOSE STUDY OF SAFETY AND EFFICACY OF RHIGF-1 ADMINISTERED FOR THERAPY

PHASE II DOSE STUDY OF SAFETY AND EFFICACY OF RHIGF-1 ADMINISTERED FOR THERAPY
RHIGF-1 治疗安全性和有效性的 II 期剂量研究
批准号:
3743545
负责人:
EUGENE J BARRETT
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

EUGENE J BARRETT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
New treatments are sought for NIDDM, focussing on methods to improve metabolic control while avoiding hyperinsulinemia. When diet and exercise fail, all current treatment options usually cannot meet those goals. rhIGF-I is an agent with blood glucose lowering effects when given in pharmacologic doses, while suppressing endogenous insulin secretion. This study is a multicenter, dose finding trial funded by Genentech Inc., manufacturer of rhIGF-1, to assess efficacy and safety of rhIGF-1 in the treatment of NIDDM.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
REGULATION OF SKELETAL MUSCLE PROTEIN METABOLISM IN MAN
  • 批准号:
    3237991
  • 项目类别:
  • 资助金额:
    $15.73万
  • 财政年份:
    1987
  • 负责人:
    EUGENE J BARRETT
  • 依托单位:
REGULATION OF SKELETAL MUSCLE PROTEIN BY EPINEPHRINE
  • 批准号:
    3765651
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    EUGENE J BARRETT
  • 依托单位:
REGULATION OF SKELETAL MUSCLE PROTEIN TURNOVER--MECHANISM OF INSULIN'S ACTION
  • 批准号:
    3765653
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    EUGENE J BARRETT
  • 依托单位:
REGULATION OF SKELETAL MUSCLE PROTEIN BY EPINEPHRINE
  • 批准号:
    3787747
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    EUGENE J BARRETT
  • 依托单位:
海外基金